REFERENCES
1.European Heart Rhythm A， European Association for Cardio-Thoracic S， Camm AJ， Kirchhof P， Lip GY， Schotten U， Savelieva I， Ernst S， Van Gelder IC， Al-Attar N， Hindricks G， Prendergast B， Heidbuchel H， Alfieri O， Angelini A， Atar D， Colonna P， De Caterina R， De Sutter J， Goette A， Gorenek B， Heldal M， Hohloser SH， Kolh P， Le Heuzey JY， Ponikowski P， Rutten FH， Guidelines ESCCfP. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360-1420.
2.Camm AJ， Lip GY， De Caterina R， Savelieva I， Atar D， Hohnloser SH， Hindricks G， Kirchhof P， Guidelines-CPG ESCCfP， Document R. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.
3.Roy D， Talajic M， Nattel S， Wyse DG， Dorian P， Lee KL， Bourassa MG， Arnold JM， Buxton AE， Camm AJ， Connolly SJ， Dubuc M， Ducharme A， Guerra PG， Hohnloser SH， Lambert J， Le Heuzey JY， O’Hara G， Pedersen OD， Rouleau JL， Singh BN， Stevenson LW， Stevenson WG， Thibault B， Waldo AL， Atrial F， Congestive Heart Failure I. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677.
4.Wyse DG， Waldo AL， DiMarco JP， Domanski MJ， Rosenberg Y， Schron EB， Kellen JC， Greene HL， Mickel MC， Dalquist JE， Corley SD， Atrial Fibrillation Follow-up Investigation of Rhythm Management I. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
5.Opolski G， Torbicki A， Kosior DA， Szulc M， Wozakowska-Kaplon B， Kolodziej P， Achremczyk P， Investigators of the Polish How to Treat Chronic Atrial Fibrillation S. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126:476-486.
6.Hohnloser SH， Kuck KH， Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-1794.
7.Calkins H， Kuck KH， Cappato R， Brugada J， Camm AJ， Chen SA， Crijns HJ， Damiano RJ， Jr.， Davies DW， DiMarco J， Edgerton J， Ellenbogen K， Ezekowitz MD， Haines DE， Haissaguerre M， Hindricks G， Iesaka Y， Jackman W， Jalife J， Jais P， Kalman J， Keane D， Kim YH， Kirchhof P， Klein G， Kottkamp H， Kumagai K， Lindsay BD， Mansour M， Marchlinski FE， McCarthy PM， Mont JL， Morady F， Nademanee K， Nakagawa H， Natale A， Nattel S， Packer DL， Pappone C， Prystowsky E， Raviele A， Reddy V， Ruskin JN， Shemin RJ， Tsao HM， Wilber D， Heart Rhythm Society Task Force on C， Surgical Ablation of Atrial F. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection， procedural techniques， patient management and follow-up， definitions， endpoints， and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA)， a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC)， American Heart Association (AHA)， the Asia Pacific Heart Rhythm Society (APHRS)， and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation， the American Heart Association， the European Cardiac Arrhythmia Society， the European Heart Rhythm Association， the Society of Thoracic Surgeons， the Asia Pacific Heart Rhythm Society， and the Heart Rhythm Society. Heart Rhythm. 2012;9:632-696 e621.
8.Santangeli P， Di Biase L， Burkhardt JD， Bai R， Mohanty P， Pump A， Natale A. Examining the safety of amiodarone. Expert Opin Drug Saf. 2012;11:191-214.
9.Roy D， Talajic M， Dorian P， Connolly S， Eisenberg MJ， Green M， Kus T， Lambert J， Dubuc M， Gagne P， Nattel S， Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-920.
10.Nichol G， McAlister F， Pham B， Laupacis A， Shea B， Green M， Tang A， Wells G. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart. 2002;87:535-543.
11.Corley SD， Epstein AE， DiMarco JP， Domanski MJ， Geller N， Greene HL， Josephson RA， Kellen JC， Klein RC， Krahn AD， Mickel M， Mitchell LB， Nelson JD， Rosenberg Y， Schron E， Shemanski L， Waldo AL， Wyse DG， Investigators A. Relationships between sinus rhythm， treatment， and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-1513.
12.Pedersen OD， Brendorp B， Elming H， Pehrson S， Kober L， Torp-Pedersen C. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev. 2003;7:220-224.
13.Deedwania PC， Singh BN， Ellenbogen K， Fisher S， Fletcher R， Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98:2574-2579.
14.Santangeli P， Di Biase L， Pelargonio G， Burkhardt JD， Natale A. The pharmaceutical pipeline for atrial fibrillation. Ann Med. 2011;43:13-32.
15.Calkins H， Reynolds MR， Spector P， Sondhi M， Xu Y， Martin A， Williams CJ， Sledge I. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2:349-361.
16.Khan MN， Jais P， Cummings J， Di Biase L， Sanders P， Martin DO， Kautzner J， Hao S， Themistoclakis S， Fanelli R， Potenza D， Massaro R， Wazni O， Schweikert R， Saliba W， Wang P， Al-Ahmad A， Beheiry S， Santarelli P， Starling RC， Dello Russo A， Pelargonio G， Brachmann J， Schibgilla V， Bonso A， Casella M， Raviele A， Haissaguerre M， Natale A， Investigators P-C. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778-1785.
17.Jones DG， Haldar SK， Hussain W， Sharma R， Francis DP， Rahman-Haley SL， McDonagh TA， Underwood SR， Markides V， Wong T. A Randomized Trial to Assess Catheter Ablation versus Rate Control in the Management of Persistent Atrial Fibrillation in Heart Failure (ARC-HF). J Am Coll Cardiol. 2013.
18.Chen MS， Marrouche NF， Khaykin Y， Gillinov AM， Wazni O， Martin DO， Rossillo A， Verma A， Cummings J， Erciyes D， Saad E， Bhargava M， Bash D， Schweikert R， Burkhardt D， Williams-Andrews M， Perez-Lugones A， Abdul-Karim A， Saliba W， Natale A. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol. 2004;43:1004-1009.
19.Hsu LF， Jais P， Sanders P， Garrigue S， Hocini M， Sacher F， Takahashi Y， Rotter M， Pasquie JL， Scavee C， Bordachar P， Clementy J， Haissaguerre M. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.
20.Gentlesk PJ， Sauer WH， Gerstenfeld EP， Lin D， Dixit S， Zado E， Callans D， Marchlinski FE. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:9-14.
21.Efremidis M， Sideris A， Xydonas S， Letsas KP， Alexanian IP， Manolatos D， Mihas CC， Filippatos GS， Kardaras F. Ablation of atrial fibrillation in patients with heart failure: reversal of atrial and ventricular remodelling. Hellenic J Cardiol. 2008;49:19-25.
22.Lutomsky BA， Rostock T， Koops A， Steven D， Mullerleile K， Servatius H， Drewitz I， Ueberschar D， Plagemann T， Ventura R， Meinertz T， Willems S. Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging. Europace. 2008;10:593-599.
23.De Potter T， Berruezo A， Mont L， Matiello M， Tamborero D， Santibanez C， Benito B， Zamorano N， Brugada J. Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace. 2010;12:24-29.
24.Choi AD， Hematpour K， Kukin M， Mittal S， Steinberg JS. Ablation vs medical therapy in the setting of symptomatic atrial fibrillation and left ventricular dysfunction. Congest Heart Fail. 2010;16:10-14.
25.MacDonald MR， Connelly DT， Hawkins NM， Steedman T， Payne J， Shaw M， Denvir M， Bhagra S， Small S， Martin W， McMurray JJ， Petrie MC. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011;97:740-747.
26.Chatterjee NA， Upadhyay GA， Ellenbogen KA， Hayes DL， Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail. 2012;14:661-667.
[1] [2] [3] 4 [上一页]